Companies · Other Health Care
IRVING · Other Health Care
Diligence memoA one-page analyst read on TW-NHME Holdings Corp. — recommendation, valuation, rhythm, risks.→TW-NHME Holdings Corp. looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
TW-NHME Holdings Corp. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
TW-NHME Holdings Corp. is one of 5377 Other Health Care companies tracked from IRVING. By capital raised it ranks among the largest (ahead of 94% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 20%.
Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.
Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 94% of sector peers (real $). Modeled value above 86% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #36 of 40.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Specialty Networks, LLC | Series C | $94.5M | $2.2B | 2.08× |
| New MMI Holdings, Inc. | Series C | $80.7M | $1.8B | 1.77× |
| BioMatrix Holdings, L.L.C. | Series C | $80.0M | $1.8B | 1.76× |
| Sea Hunter Holdings, LLC | Series C | $76.3M | $1.7B | 1.68× |
| Bind Benefits, Inc. | Series C | $70.0M | $1.6B | 1.54× |
| Endotronix Inc | Series C | $116.1M | $1.6B | 1.52× |
| Great Basin Scientific, Inc. | Series C | $124.3M | $1.6B | 1.49× |
| TransMedics, Inc. | Series C | $249.0M | $1.5B | 1.40× |
| Landmark Health, LLC | Series C | $90.8M | $1.4B | 1.34× |
| Rapid Micro Biosystems, Inc. | Series C | $134.6M | $1.4B | 1.32× |
| Mdp Acm Holdings, Llc | Series C | $60.0M | $1.4B | 1.32× |
| ACON BioMatrix Investors I, L.L.C. | Series C | $57.5M | $1.3B | 1.26× |
| TW-NHME Holdings Corp. this company | Series C | $64.3M | $171.5M | 0.16× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series C | $43.1M | 2015-07-14 | $287.7M | $986.5M | 85% |
| Series C | $10.8M | 2016-01-05 | $72.0M | $246.9M | 85% |
| Series C | $2.8M | 2016-06-30 | $18.9M | $64.9M | 85% |
| Series C | $7.5M | 2018-03-29 | $50.0M | $171.5M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Geoffrey S. Raker | — | 5 other | 2015-07 |
| JAMES S. HOCH | — | 4 other | 2015-07 |
| CHRISTOPHER M. TEMPLE | — | 1 other | 2015-07 |
| MICHAEL S. MILLER | — | 1 other | 2015-07 |
| ALAN L. DAHL | — | — | 2015-07 |
| ALAN M. DAHL | — | — | 2018-03 |
| DAVE M. GASMIRE | — | — | 2018-03 |
| EMILY M. BUXTON | — | — | 2018-03 |
| ENABNIT S. TAYLOR | — | — | 2015-07 |
| JONATHAN L. LEVY | — | — | 2015-07 |
| Taylor S. Enabnit | — | — | 2016-01 |
| WILLIAM MONAST | — | — | 2015-07 |
TW-NHME Holdings Corp. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Calypso Medical Technologies Inc | Other Health Care | Series C | $69.5M | $171.5M | same sector · same stage |
| Cytrellis Biosystems, Inc. | Other Health Care | Series C | $82.7M | $182.1M | same sector · same stage |
| TW Lone Peak Master, LLC | Other Health Care | Series B | $21.6M | $477.6M | network1 shared operator · same sector |
| Calyxo, Inc. | Other Health Care | Series C | $115.9M | $204.9M | same sector · same stage |
| MicroTransponder, Inc. | Other Health Care | Series C | $117.7M | $223.3M | same sector · same stage |
| Fourth Edge LLC | Other Health Care | Series C | $119.7M | $222.0M | same sector · same stage |
| TRIA Beauty, Inc. | Other Health Care | Series C | $155.9M | $194.4M | same sector · same stage |
| Vavotar Life Sciences LLC | Other Health Care | Series C | $156.0M | $228.6M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| TMRW Life Sciences Holdings, LLC | Other Health Care | Series A | $242.2M | 87% |
| TMRW Life Sciences, Inc. | Other Health Care | Series D+ | $284.2M | 87% |
| NorCal Holding Company, Inc. | Other Health Care | Series A | $100.9M | 85% |
| TCH Group, Inc. | Other Health Care | Series B | $487.9M | 85% |
| tEMed Holdings LLC | Other Health Care | Series A | $121.1M | 85% |
| WM & DG, Inc. | Other Health Care | Pre-Seed | $14.8M | 84% |
| TGHCo, Inc. | Other Health Care | Series B | $178.2M | 84% |
| M2Gen Holdings, L.P. | Other Health Care | Pre-Seed | $12.2M | 84% |
See where TW-NHME Holdings Corp. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at TW-NHME Holdings Corp., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.